Vivos Therapeutics, Inc. Material Event - What Happened

Hey there! Let's break down what's going on with Vivos Therapeutics in a way that makes sense, without all the fancy finance talk. Think of this as me explaining a news story to you over coffee.

---

1. What happened?

Okay, so here's the big news:

• Vivos Therapeutics just secured a new loan, or what's called a "Promissory Note," from a company called Avondale Capital, LLC. They're borrowing a total of $2,093,340, but after some upfront fees and discounts, Vivos actually received about $1,500,000 in cash.
• What does that mean? It means Vivos got a cash injection, but it's a loan they have to pay back, not money from selling new shares. This loan is unsecured, meaning there isn't specific collateral tied to it, and a Vivos subsidiary, Airway Integrated Management Company, LLC (AIM), is guaranteeing the loan.

2. When did it happen?

• This agreement was made on December 5, 2025.
• The official announcement came out on the same day, via a regulatory filing.

3. Why did it happen?

So, why did this happen? Well, it looks like:

• Vivos needed some extra cash for its day-to-day operations and other general business needs. This loan provides that "working capital."
• It suggests the company needed funds to keep things running smoothly or to pursue other opportunities.

4. Why does this matter?

Why should you care about this? Here's the deal:

• This matters because Vivos just got a significant amount of cash ($1.5 million) to help fund its operations. On one hand, getting this money means the company has the funds it needs right now.
• On the other hand, it's a loan, which means Vivos is taking on more debt and has to make regular payments. The terms are also quite specific: they borrowed a larger amount ($2.09 million) to get $1.5 million, which is like paying a big fee upfront (an "original issue discount").
• Also, a subsidiary of Vivos is guaranteeing the loan, which means if Vivos can't pay, the subsidiary is on the hook. This lender, Avondale Capital, LLC, is also an affiliate of Streeterville Capital, LLC, with whom Vivos already has a senior secured loan, suggesting a continued relationship with this financing group.

5. Who is affected?

Who's feeling the effects of this? Pretty much everyone connected to Vivos:

• The Company (Vivos Therapeutics itself): They get the much-needed cash to keep operations going and pursue their business goals. However, they also take on a new debt obligation with weekly payments.
• Investors/Shareholders: This loan doesn't dilute their ownership (meaning no new shares were issued), which is often a good thing. However, it does increase the company's debt burden. The market might view the need for this financing, and its terms, as a sign of financial pressure or as a positive step to secure necessary funds.
• Lender (Avondale Capital, LLC): They're providing the capital and will receive weekly payments back from Vivos.

6. What happens next?

So, what's next for Vivos? Good question:

• Immediately, we can expect Vivos to start using the $1.5 million for its working capital and general business needs.
• They will also begin making weekly payments of $69,778 starting December 12, 2025, until the loan is fully repaid.
• There's also an incentive for Vivos to pay back the loan early (by January 4, 2026) to get a discount of $286,140 on the total amount owed.

7. What should investors/traders know?

If you're thinking about Vivos stock, here's what you should keep in mind:

• Cash Infusion vs. Debt Burden: While Vivos received $1.5 million in cash, it comes with a significant debt obligation and weekly payments. This could be seen as a necessary step to maintain operations, but also highlights a need for external financing.
• No Dilution (for now): The good news for existing shareholders is that this isn't an equity raise, so your ownership percentage isn't immediately diluted.
• Terms of the Loan: The original issue discount (borrowing $2.09M to get $1.5M) and the weekly payment schedule are important details. The option to prepay for a discount is also notable.
• Existing Relationship: The lender is an affiliate of Streeterville Capital, LLC, which already has a senior secured loan with Vivos. This indicates a continued reliance on this financing source.
• Watch for Financial Health: Keep an eye on how Vivos uses this cash and whether it helps improve their overall financial stability and profitability in future earnings reports. The ability to make these weekly payments will be key.